Sirio Pharma Co., Ltd. Class A

Sirio Pharma Co., Ltd. Class A

SSZSE:300791
16.90
CNY
-0.46
(-2.65%)
0.00EPS
53.29P/E
5.67BMarket Cap
Apr 28Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3.06
3.41
19.34
3.45
5.84
7
6.38
6.8
7.79
8.24
11.75
13.87
13.95
13.14
Basic EPS, GAAP
0.24
0.27
1.32
3.08
0.46
0.89
0.58
0.85
0.76
0.7
0.92
1.07
0.45
0.35
Free Cash Flow per Basic Share
0.26
0.1
-1.26
-0.75
-0.48
-0.25
0.26
0.32
-0.6
0.5
-0.22
0.51
0.42
- -
Dividend per Share
0.05
0.25
3.24
1.17
0.99
0.19
0.06
0.09
0.24
0.25
0.28
0.72
0.6
0.26
Book Value per Share
0.89
0.61
1.06
2.02
2.54
3.43
6.39
7.18
8.36
8.86
7.79
8.17
9.56
10.02
Tangible Book Value per Share
0.75
0.39
0.32
0.57
1.02
1.93
5.24
6.02
7.15
7.61
4.54
4.99
6.57
7.15
Basic Weighted Avg Shares
228
228
43
228
228
228
247
304
304
304
305
304
306
307
Sales/Revenue/Turnover
699
779
824
786
1,330
1,595
1,580
2,067
2,369
2,507
3,582
4,211
4,263
4,037
Operating Margin (%)
11.72
11.18
10.68
6.78
11.86
15.9
10.24
14.75
12.45
10.34
11.01
10.43
7.71
8.44
Depreciation Expense
19
27
29
32
48
55
72
80
104
132
257
239
258
- -
Net Income, GAAP
55
61
56
704
104
203
143
257
232
212
281
325
137
106
Effective Tax Rate (%)
16.93
17.2
20.33
24.93
20.13
11.79
9.16
17.5
17.47
15.6
12.07
10.94
- -
- -
Profit Margin (%)
7.81
7.89
6.82
89.51
7.84
12.74
9.02
12.45
9.79
8.47
7.85
7.72
3.2
2.63
Working Capital
3
-128
-91
28
97
47
1,015
933
1,582
1,963
1,182
1,198
862
141
LT Debt
52
28
11
146
223
158
32
1
869
929
1,305
1,484
1,445
478
Total Equity
204
139
241
462
580
784
1,945
2,183
2,545
2,702
2,566
2,641
2,959
3,077
Return on Invested Capital (%)
18.56
19.14
13.49
94.19
10.27
18.18
8.41
12.15
8.45
6.33
6.53
7.07
- -
- -
Return on Capital (%)
20.55
22.64
16.25
105.5
12.54
19.83
9.52
12.13
8.63
7.04
10.32
11.07
- -
- -
Return on Common Equity (%)
29.38
35.89
29.6
200.13
20.02
29.8
10.45
12.47
9.81
8.09
11.04
13.28
5.01
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
284
1,507
1,486
LT Borrowings
1,213
127
263
LT Finance Leases
313
213
215
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
308
309
308
Market Capitalization
6,251
4,945
5,674

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,011
2,316
2,532
Cash, Cash Equivalents & STI
669
782
990
Accounts Receivable, Net
688
776
773
Inventories
472
596
607
Total Current Liabilities
1,090
2,383
2,391
Payables & Accruals
- -
- -
- -
ST Debt
284
1,507
1,486
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
34.52%
6.54%
12.05%
Free Cash Flow
-100.2%
-193.73%
-16.74%
Net Income, GAAP
118.28%
-5.66%
-58%
Sales/Revenue/Turnover
19.65%
16.42%
1.23%
Total Cash Common Dividend
35.14%
68.18%
-16.66%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
952
1,039
1,058
1,163
4,211
2025
954
1,087
- -
972
4,263
2026
1,003
1,049
1,013
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.21
0.3
0.28
0.28
1.07
2025
0.23
0.3
- -
-0.4
0.45
2026
0.16
0.33
0.25
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.69
0.03
-0.01
0.72
2025
0.01
0.56
- -
0.02
0.6
2026
0.01
0.22
0.01
- -
- -

Company Description

CEO
Pei Qing Lin
Full Time Employees
2,776
Sector
Health technology
Industry
Pharmaceuticals: other
Address
No.83 Taishan Road Shantou GD China 515000
IPO Date
Sep 25, 2019
Business
Sirio Pharma Co., Ltd. serves as a prominent contract development and manufacturing organization for the global nutritional and health food sector. The company specializes in the creation and production of a diverse array of nutritional products, encompassing traditional and plant-based softgels, innovative nutraceutical gummies, probiotic formulations, tablets, powders, hard capsules, and functional liquids. Beyond manufacturing, it provides comprehensive, end-to-end solutions, including product research, development, custom packaging, logistics, and marketing assistance. Established in 1993, Sirio Pharma is headquartered in Shantou, China, with an expanding international presence, including manufacturing sites in the U.S. and Europe, supporting its "globally local" strategy. The company has demonstrated consistent growth, with its 2024 annual revenue reaching RMB 4.211 billion, reflecting a 17.56% year-over-year increase.